OA23 Patient-reported outcome measure for giant cell arteritis: cross-sectional validation study
Authors: Ndosi Mwidimi , Almeida Celia , Dawson Jill , Dures Emma , Greenwood Rosemary , Guly Catherine , Mackie Sarah , Bromhead Alison , Stern Steve , Robson Joanna C 
Published: April 2022

Background/Aims

Giant cell arteritis (GCA) presents in people over the age of 50 with cranial, ocular, and large vessel vasculitis. This study aims to validate a disease-specific patient-reported outcome measure (PROM) for patients with GCA, to capture the impact of GCA and its treatment on health-related quality of life.

Methods

This cross-sectional study included UK patients with clinician-confirmed GCA; diagnosed within the last three years or flaring within the last year. Patients completed the 40 candidate PROM items, the EQ5D-5L, CAT-PROM5 and self-report of disease activity. Rasch and factor analysis were used to determine internal validity and factor structure. Item reductions were based on clinical importance, Rasch model fit, and redundancy. Tests of validity included comparison of the GCA-PROM (i) in participants with ‘active disease’ versus patients ‘in remission’ (known groups validity) and (ii) with EQ5D-5L and CAT-PROM5 scores (convergent validity).

Results

The survey included 428 patients, mean age (SD) of 74.2 (7.2), 285 (67%) female. 327 (76%) cranial GCA, 114 (26.6%) large vessel vasculitis and 142 (33.2%) ocular involvement. Positive diagnostic tests included 167 (39%) temporal artery biopsy, 177 (41.4%) temporal artery ultrasound, and 51 (11.9%) Positron Emission Tomography and Computed Tomography (PET-CT). Active disease was reported in 197 (46%). After the initial analysis (40 items), ten items were deleted, and two response categories collapsed to ensure overall fit to the Rasch model. This resulted in a final PROM comprising a 30-item scale with a 4-response category structure. Factor analysis confirmed four factors (domains): Acute symptoms (8 items), Activities of daily living (7 items), Psychological (7 items) and Participation (8 items), all of which individually fitted the Rasch model (X2 = 25.219, DF = 24, p = 0.394 including reliability [Person Separation Index, PSI=0.828]), (construct validity). Each domain correlated, at least moderately, with EQ5D-5L and CAT-PROM5 scores (Spearman’s Correlation Coefficients 0.44 to 0.78) (convergent validity). The new GCA-PRO discriminated between patients with active disease and remission (known groups validity) (Table 1).

Conclusion

The 30-item GCA-PROM demonstrates internal and external validity in measuring health-related quality of life in people with GCA.

Disclosure

M. Ndosi: None. C. Almeida: None. J. Dawson: None. E. Dures: None. R. Greenwood: None. C. Guly: None. S. Mackie: Honoraria; Sept 2021: Roche/Chugai payment to my institution for delivering a talk on giant cell arteritis at an educational day. Grants/research support; MRC Confidence in Concept scheme, 2021 Grant to develop early diagnosis methods for giant cell arteritis, 2018: MRC Proximity to Discovery: Protein biomarkers for polymyalgia rheumatica and giant cell arteritis (PI: Morgan, University of Leeds), 2019: Roche: giant cell arteritis tocilizumab registry (PI: Morgan, University of Leeds). Other; Site Sub-Investigator on clinical trial in giant cell arteritis for Roche, Site Principal Investigator on clinical trial in giant cell arteritis for GSK, Site Principal Investigator and UK Chief Investigator on clinical trials (giant cell arteritis and polymyalgia rheumatica) for Sanofi. A. Bromhead: None. S. Stern: None. J.C. Robson: None.